Drug Harm Reduction Guide
Evidence-based harm reduction information for all major substance categories. Acknowledges substance use as a public health reality and prioritizes risk minimization. All content is informational only, based on publicly available medical and public health research.
Universal Harm Reduction Principles
Harm reduction is a public health framework that recognizes substance use as a social reality and works to reduce its associated risks rather than eliminating use through prohibition alone. Harm reduction approaches have demonstrated effectiveness in reducing overdose mortality, infectious disease transmission, and substance use disorder severity.
- Test every substance. Reagent test kits (Marquis, Mecke, Mandelin, Simon's, Froehde) identify major adulterants. Fentanyl test strips detect fentanyl and fentanyl analogues across substance classes. Laboratory drug checking services provide precise quantitative analysis where available.
- Start low, go slow. Unknown purity and inconsistent batch quality make every new supply unpredictable. Conservative initial dosing with gradual adjustment eliminates the most common dose-related emergency scenarios.
- Never use alone. Supervised drug consumption services, remote check-in apps (Never Use Alone hotline: 1-800-484-3731 in the US), and trusted companions significantly reduce fatal outcome probability.
- Avoid mixing. Polydrug combinations — particularly CNS depressants (opioids, benzos, alcohol, GHB) — multiply respiratory depression risk in a non-additive way. Many overdose deaths involve multiple substances.
- Know your route. Each administration route carries different onset times, peak intensities, and risk profiles. IV use carries the highest infectious disease and overdose risk.
- Carry naloxone. Naloxone (Narcan) is a fast-acting opioid antagonist available over the counter in most US states and through many harm reduction organizations globally. Carry it at all times when opioids are present.
EMERGENCY: If someone is unresponsive, not breathing normally, or has blue lips/fingertips — call emergency services immediately (911 in US, 999 in UK, 112 in EU). Administer naloxone if opioids are suspected. Place in recovery position. Do not leave the person alone.
- Unresponsive / unconscious
- Slow, shallow, or stopped breathing
- Blue or grey lips and fingernails (cyanosis)
- Gurgling or snoring breathing sounds
- Pinpoint pupils (opioids)
- Chest pain or irregular heartbeat (stimulants)
- Seizures or uncontrolled muscle movement
- Extremely high body temperature
Naloxone — Opioid Overdose Reversal
Naloxone (brand names Narcan, Kloxxado, Evzio) is an opioid antagonist that rapidly reverses opioid overdose by displacing opioids from receptors in the brain. It is safe, fast-acting, and can be administered by bystanders with minimal training. Naloxone has no effect in the absence of opioids — it cannot harm someone who has not used opioids.
Administration Methods
- Nasal spray (Narcan): Insert nozzle into one nostril, press plunger firmly. Repeat in other nostril after 2-3 minutes if no response. Most practical for bystander administration.
- Auto-injector (Evzio): Inject into outer thigh, through clothing if necessary. Provides audio instructions during administration.
- Injectable ampules: Require medical training for IV/IM administration. Most common in clinical settings.
After Administering Naloxone
- Call emergency services immediately (naloxone is a bridge, not a cure).
- Place the person in the recovery position (on their side) to prevent choking.
- Naloxone wears off in 30-90 minutes — the overdose can return if long-acting opioids were used. Multiple doses may be required.
- Do not leave the person alone until emergency services arrive.
- Fentanyl overdoses often require 2-3 nasal spray doses or repeated administration due to potency.
Substance-Specific Harm Reduction
Includes heroin, oxycodone, hydrocodone, fentanyl, tramadol. Primary risks: respiratory depression, overdose, dependence. Test for: fentanyl and analogues (FTS). Never: mix with benzos, alcohol, or other depressants. Carry: naloxone always. Overdose: administer naloxone, call 911, recovery position.
Synthetic opioid 50-100× potency of morphine. Present in counterfeit pills and other substances as adulterant. Test: fentanyl test strips on all substances. Dose: Lethal doses measured in micrograms — visual estimation is impossible. Multiple naloxone doses typically required due to potency. Never use alone.
CNS stimulant. Primary risks: cardiac arrhythmia, hypertension, stroke, hyperthermia, seizure. Test for: fentanyl (increasingly present in cocaine supply), levamisole. Avoid: combining with alcohol (creates cocaethylene), opioids, or other stimulants. Overdose: cool the person, call emergency services. Naloxone ineffective.
Entactogen / stimulant. Primary risks: hyperthermia, hyponatremia (overhydration), serotonin syndrome (with SSRIs/MAOIs). Test: Marquis (purple-black = positive), Mecke, Simon's. Hydration: 500ml water per hour — not more. Temperature: take cooling breaks if dancing. Never mix: with MAOIs, SSRIs, lithium, tramadol.
Potent CNS stimulant. Primary risks: cardiovascular stress, hyperthermia, psychosis with heavy use, severe dependence. Test: Marquis (orange → brown), Simon's (differentiates from amphetamine). Never: combine with MAOIs. Overdose: cool the body, call emergency services, prevent self-harm if psychotic episode presents.
CNS depressants including diazepam, alprazolam, clonazepam. Primary risks: respiratory depression (especially in combination), severe withdrawal syndrome with abrupt cessation. Never mix: with opioids, alcohol, or GHB/GBL — combination is frequently fatal. Dependence: physical withdrawal is medically serious — requires supervised tapering.
THC content varies widely between products. Primary risks: acute anxiety/panic (especially with high-THC, inexperienced users), cannabis hyperemesis syndrome with chronic heavy use, impaired coordination. Edibles: onset 45-120 min — do not re-dose before onset. CBD: can attenuate THC effects — useful for anxiety management.
Serotonergic psychedelics including LSD, psilocybin, DMT, mescaline. Primary risks: challenging psychological experiences, HPPD (rare). Low physiological toxicity — no known lethal dose for LSD/psilocybin. Test LSD: Ehrlich reagent (purple = indole compound). Set & setting are primary determinants of experience quality.
CNS depressant with narrow dose-response curve. Primary risks: unconsciousness, respiratory depression, extreme sensitivity to dose — 0.5ml can separate a recreational dose from an overdose. Never mix: with alcohol, opioids, benzos. Overdose: recovery position, call emergency services. Withdrawal can be fatal — requires medical supervision.
Dissociative anesthetic. Primary risks: bladder damage with chronic use (ketamine cystitis — irreversible), emergence phenomena, respiratory depression at very high doses. Test: Marquis (no reaction), Simon's (no reaction) — differentiate from PCP. K-hole: a high-dose dissociative state — not an overdose but requires safe environment.
Including amphetamine sulfate, Adderall. Primary risks: cardiovascular stress, hyperthermia, psychosis with heavy use. Test: Marquis (orange → red-brown), Froehde. Avoid: MAOIs, stimulant combinations. Sleep: ensure adequate rest between uses. Overdose: cool body, call emergency services, prevent seizure injury.
Research chemicals and novel psychoactive substances have limited safety data. Primary risks: unknown — unpredictable pharmacology, unknown toxic thresholds, no established overdose treatment protocols. Testing: reagent testing for class identification, but class ≠ specific compound. Extreme caution: always. Never combine. Never redose before full onset.
Drug Testing Resources
Drug testing is one of the most impactful harm reduction practices available. Fentanyl contamination has entered nearly every illicit drug supply — testing before use saves lives.
| Test Type | What It Detects | Substances |
|---|---|---|
| Fentanyl Test Strips | Fentanyl and most analogues | Any dissolved substance |
| Marquis Reagent | MDMA, amphetamines, opioids (color-based) | Wide spectrum |
| Mecke Reagent | Opioids, MDMA, DXM | Distinguishes from Marquis result |
| Mandelin Reagent | Ketamine, amphetamines, opioids | Ketamine identification |
| Simon's Reagent | MDMA vs MDA (secondary amines) | MDMA identification |
| Ehrlich Reagent | Indole compounds (LSD, DMT, psilocybin) | Psychedelic verification |
| FTIR / Lab Testing | Quantitative — precise compound ID | All substances (requires equipment) |